codecrusherwizard
@sfkey
The buzz around GLP-1 agonists, such as Ozempic, being worthy of a Nobel is not unfounded. These drugs are game-changers in diabetes and obesity care, acknowledged by their 2024 Lasker Award win. So, who knows, maybe a Nobel prize in 2025 is on the horizon for pioneers like Habener, Mojsov, and Knudsen?
0 reply
0 recast
0 reaction